SCHEMBL16616727

SCHEMBL16616727

O=Cc1cccnc1Cc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.49
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
NFE2L2 Q16236 1/20 0.41
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSP90AA1 P07900 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
KAT2B Q92831 1/20 0.38
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20767501 0.85 PARP1 (0.45) PARP1TRIM24TRIM33NFE2L2SMN1; SMN2
SCHEMBL17595558 0.84 TRIM24 (0.48) PARP1TRIM24TRIM33ALDH1A1HTT
SCHEMBL27721079 0.80 MAOB (0.44) TRIM24TRIM33NFE2L2ALDH1A1SMN1; SMN2
SCHEMBL26683429 0.79 PARP1 (0.50) PARP1SMN1; SMN2CYP1A2CYP2C19HSP90AA1
SCHEMBL10696454 0.77 PARP1 (0.49) PARP1SMN1; SMN2CYP1A2CYP2C19HSP90AA1
SCHEMBL17225909 0.77 TRIM24 (0.52) TRIM24TRIM33NFE2L2ALDH1A1HTT
SCHEMBL27742004 0.76 MEN1 (0.49) TRIM24TRIM33ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL13851903 0.75 L3MBTL1 (0.55) ALDH1A1CYP1A2CYP2C19KMT2AMEN1
SCHEMBL15738996 0.74 KMT2A (0.53) PARP1ALDH1A1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL17183939 0.73 PARP1 (0.46) PARP1ALDH1A1SMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210300872-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS UNIVERSITY OF KANSAS 2021-09-30 US disclosed
US-11028041-B2 Second generation GRP94-selective inhibitors UNIVERSITY OF KANSAS (US) 2021-06-08 US disclosed
US-20200190017-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS UNIVERSITY OF KANSAS 2020-06-18 US disclosed
WO-2019040792-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS UNIVERSITY OF KANSAS (US) 2019-02-28 WO disclosed
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300872-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS HSP90B1, HSP90AB2P, HSPE1 PARP1 4526/4885TRIM24 1109/4885TRIM33 2080/4885
US-11028041-B2 Second generation GRP94-selective inhibitors HSP90B1, HSP90AB2P, HSPE1 PARP1 4481/4885TRIM24 1104/4885TRIM33 2021/4885
US-20200190017-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS HSP90B1, HSP90AB2P, HSPE1 PARP1 4481/4885TRIM24 1104/4885TRIM33 2021/4885
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof HCCS, WEE2, WEE1 PARP1 3631/4885TRIM24 2332/4885TRIM33 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.